Objectives: The increasing use of chlorhexidine for methicillin-resistant Staphylococcus aureus (MRSA) decolonization raises concerns about reduced susceptibility. We evaluated the carriage of chlorhexidine resistance genes and chlorhexidine susceptibility in MRSA before and after introduction of an institutional MRSA control programme incorporating chlorhexidine-based decolonization in 2004.
Introduction
Biocides play an important role in the control of microbial pathogens in hospitals. 1, 2 Chlorhexidine gluconate is a water-soluble, cationic biguanide that disrupts the plasma membrane, resulting in biocidal activity at high concentrations. 1, 3 It is probably the leading antiseptic biocide and is used for a variety of indications, 4 -6 including the decolonization of patients with methicillin-resistant Staphylococcus aureus (MRSA). 1,3 -7 The widespread use of chlorhexidine has probably been facilitated by an assumption that the selection of organisms with clinically significant reduced chlorhexidine susceptibility is rare. 2, 8 Clinically significant reduced susceptibility to chlorhexidine in S. aureus has been hard to define for a number of reasons. Firstly, there is no generally agreed methodology for detecting reduced chlorhexidine susceptibility. 1,7,9 -13 Secondly, population MICs vary by lineage, making a meaningful breakpoint difficult to determine, 13 and higher MICs displayed by some isolates (4 -16 mg/L) are still well below the effective chlorhexidine concentration applied to skin (10 000-40 000 mg/L). 14, 15 Thirdly, although genes encoding membrane efflux pumps have been identified in S. aureus, including qacA, qacB and smr, these have an unclear association with higher MICs or MBCs. 1, 2, 7 Fourthly, other mechanisms of reduced susceptibility, such as decreased uptake of chlorhexidine, may confound the apparent effect of efflux pumps. 2, 7, 16 Finally, although many studies have reported on qacA carriage or reduced chlorhexidine susceptibility in S. aureus isolates, few have evaluated clinically relevant outcomes. 7, 8, 17, 18 Following the success of a chlorhexidine decolonization protocol on our intensive care unit (ICU), 8 its use was re-enforced as an important component of the institutional MRSA infection control campaign from 2004. 19 We therefore evaluated the carriage of qacA, qacB and smr and in vitro chlorhexidine susceptibility in MRSA bloodstream infection (BSI) isolates between 2001 and 2009.
Methods

Infection control practice
A chlorhexidine-based antiseptic protocol for all admissions to the ICU and the linked high-dependency units was introduced in April 2004, as described previously. 8, 20 Guidelines existed recommending the use of chlorhexidine for skin decolonization with nasal mupirocin for known MRSA-colonized patients on general wards throughout the study; however, a programme of education and auditing adherence to guidelines began following the success of the decolonization policy on our ICU in 2004, leading to a documented increase in decolonization practice.
Molecular analysis and antimicrobial susceptibility testing of MRSA isolates
The first MRSA BSI isolate for each patient identified between 2001 and 2009 was characterized by spa type, 21 staphylococcal cassette chromosome mec (SCCmec) allotype 22 and susceptibility to methicillin, erythromycin, ciprofloxacin, trimethoprim, gentamicin, tetracycline, rifampicin, mupirocin, linezolid and fusidic acid, using the disc diffusion method according to BSAC guidelines. 23 Clones were defined using Based Upon Repeat Pattern clustering of spa types with a stringent calculated cost between lineages of 1. 24 Isolates were assigned to CC22, CC30 or ST239-TW (a previously reported ICU-outbreak clone) 8 or defined as 'sporadic'.
Single nucleotide polymorphism (SNP) genotype assays were designed to discriminate qacA and qacB and to identify smr. Sequences for five qacA and six qacB genes downloaded from GenBank were aligned in BioEdit version 7.0.8.0. 25 The SNP at codon 291 was chosen to differentiate qacA and qacB (Table S1 , available as Supplementary data at JAC Online). 26 Reactions used TaqMan w Genotyping Master Mix with ready-mixed primers and probes (Life Technologies, Warrington, UK) to a final volume of 10 mL, containing 2 mL of template with 0.9 mM of each primer and 0.2 mM of each probe. The PCR cycle conditions were 10 min at 958C, then 40 cycles of 958C for 15 s and 608C for 1 min.
Two smr gene sequences were downloaded from GenBank, aligned using BioEdit 25 and primers and probes designed and checked using NCBI Primer-BLAST (Table S1 , available as Supplementary data at JAC Online). Reactions used Fast Advanced Master Mix (Life Technologies), 0.3 mM of each primer, 0.15 mM probe, 1 mM IPC mix (Universal Exogenous qPCR Positive Control, Eurogentec), 1 mM IPC DNA (Eurogentec) and 1 mL of template in 10 mL. The PCR cycle conditions were 508C for 2 min and 958C for 20 s, then 40 cycles of 958C for 3 s and 608C for 30 s. Samples with a C T value ,30 were considered positive for qacA, qacB and smr.
In vitro chlorhexidine susceptibility
Chlorhexidine MICs were determined for representative qacA+, smr+ and qacA+/smr+ CC22 and CC30 isolates and a similar number of yearmatched double-negative CC22 and CC30 isolates, and qacA+ ST239-TW isolates (137 in total). There were only a small number of smr+ CC22 isolates (n¼3), qacA+ CC30 isolates (n¼8) and qacA+/ smr+ isolates (n ¼2).
The chlorhexidine MIC was determined using a modified CLSI method.
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A 2-fold dilution series, from 32 to 0.0625 mg/L, was prepared fresh from a 20% (w/w) chlorhexidine gluconate solution (Sigma) and inoculated in 100 mL volumes into a 96-well microtitre tray. A 0.5+0.05 McFarland standard suspension from an overnight MRSA culture was prepared in MuellerHinton broth (Oxoid). The suspension was diluted to 5×10 6 cfu/mL and 100 mL was added per well for overnight incubation at 378C. The turbidity was assessed using an inverted microtitre plate reader (MIC2000, Cooke Laboratory Products, Alexandria, VA, USA). The MIC was the concentration of chlorhexidine in the first well in which no turbidity was seen. MICs for all isolates were determined on two separate days, with discrepant results (,10%) resolved with a further repeat.
Statistical analysis
Segmented Poisson regression was used to estimate temporal trends of BSIs, as described previously. 28 Temporal trends for the proportion of isolates by each clone were analysed using separate binomial generalized linear models with logit link functions, with time as the independent variable. Separate binomial generalized linear models were also used to assess temporal changes in qacA and smr carriage for each clone.
The preliminary exploration of associations between variables and the carriage of qacA was conducted through univariate logistic regression analyses. The association between clone and qacA carriage was assessed using multiple logistic regression including variables associated with qacA carriage in the univariate analysis (P,0.05). Interaction terms between clone and each independent variable were also assessed.
Preliminary assessment of the association between chlorhexidine MIC ≥2 mg/L and other variables was explored with univariate logistic regression analyses. Multiple logistic regression was conducted to investigate potential predictors of chlorhexidine MIC ≥2 mg/L, including variables that were significant in the univariate analysis (P,0.05). Interaction terms between clone and each independent variable were also assessed. Analyses were performed using SPSS (v19, IBM, New York) or R. The qacA, qacB and smr genes were found in 158 (26.2%), 2 (0.3%) and 49 (8.1%) isolates, respectively, with 4 (0.7%) isolates carrying both qacA and smr. The qacA carriage rates between clonal groups ranged from 5.1% to 94.8% (P,0.001; Figure 1b) ; however, across all clonal groups combined, there was no significant trend increase in qacA carriage (OR, 1.12; CI, 0.99 -1.28; P¼ 0.115). The smr carriage rates between clonal groups ranged from 0.0% to 19.3% (P,0.001; Table S2 , available as Supplementary data at JAC Online). The smr carriage overall was initially higher than that of qacA in 2001 (20.2% versus 13.1%), particularly in CC30 (34.1% versus 4.5%), but decreased significantly over the 9 years in CC22 (OR, 0.16; CI, 0.10-0.23; P,0.0001), CC30 (OR, 0.58; CI, 0.40 -0.80; P ¼0.008) and in all clones combined (OR, 0.54; CI, 0.41 -0.67; P¼ 0.0004) (Figure 1c) .
Univariate analyses demonstrated an association between the carriage of qacA and the clonal group, CC22 isolates after 2003, resistance to an increasing number of non-b-lactam antimicrobial classes and smr carriage ( Table 1 ). The carriage of qacA was associated with resistance to an increased number of non-b-lactam antimicrobial classes in all four lineages (Figure 1d ). In multiple logistic regression analysis, changes in qac carriage after 2003 depended on clone (P,0.001); CC22 isolates identified after 2003 were significantly more likely to carry qacA than CC30 identified after 2003 (OR, 7.21; CI, 1.32-39.17) ( Table 2 ).
The population chlorhexidine MIC profiles of CC22, CC30 and ST239-TW were comparable to 135/137 (98.5%) isolates having an MIC of either 2 mg/L (73.7%) or 1 mg/L (24.8%). Univariate analysis showed that the carriage of qacA in CC22 isolates was associated with a chlorhexidine MIC ≥2 mg/L, whereas carriage of qacA in CC30 isolates was associated with a chlorhexidine MIC ,2 mg/L (Table 3 ). In multiple logistic regression analysis, CC22 isolates carrying qacA were more likely to have a chlorhexidine MIC ≥2 mg/L than CC30 isolates carrying qacA (OR, 21.67; CI, 2.54 -185.20) (Table 4) . Otter et al.
Discussion
The primary aim of this study was to determine whether qacA was selected among MRSA BSI isolates in response to an effective institutional MRSA control programme that included chlorhexidine-based decolonization. Our previous ICU study identified increased transmission of the qacA+ ST239-TW clone after introduction of the decolonization protocol 8, 17 and another study observed an increase in qacA carriage among ST239 isolates over time in Taiwan. 9 There is therefore evidence that qacA is associated with a selective advantage for MRSA ST239; however, this may not occur with other MRSA clones. Clone-specific effects could explain the difference in reported MRSA qacA carriage rates despite chlorhexidine being an integral part of antisepsis worldwide. 7,9,12 -15,30 -33 The carriage of qacA increased in one (CC22), but not another (CC30), dominant endemic clone and although MRSA BSI rates fell overall, the relative prevalence of CC22 increased. Clonal replacement of CC30 with CC22 has been observed nationally in the context of declining overall rates in response to the national MRSA control campaign. 34 These changes may be explained by a significant effect of chlorhexidine on CC30, but not CC22, isolates combined with other important interventions, particularly hand hygiene, which would have an effect on all clones.
The relationship between the carriage of antiseptic resistance genes and chlorhexidine susceptibility in vitro is unclear; particularly since qacA, qacB and smr are neither necessary nor sufficient for reduced chlorhexidine susceptibility assessed using standard methodologies, such as MIC or MBC. 9,12 -14,35 Indeed, one recent study restricted the analysis of MRSA decolonization failure to the detection of qacA without presenting phenotypic data, perhaps for this reason. 18 There is also no agreed MIC cut-off for defining reduced susceptibility. 2 Some have suggested an MIC cut-off of ≥4 mg/L, 9,13 since the chlorhexidine MIC for MRSA is often ,4 mg/L. 1,9 -12 However, since few studies have evaluated clinical outcomes, this cut-off has been arbitrarily assigned based on the population of S. aureus under study, which varies by clone. 13 We used an MIC cut-off of ≥2 mg/L, since ,1% of Selection for qacA carriage in MRSA 995 JAC isolates had an MIC ≥4 mg/L. Using this MIC cut-off, we identified a significant association with a clone that was slower to decline in prevalence and in which qacA carriage increased over time.
Further work using larger datasets is required to confirm this association. Presumably, an MIC of 1 mg/L compared with 2 mg/L does not represent an in vivo chlorhexidine concentration required for distinct clinical outcomes, nor can it form the basis of a useful in vitro susceptibility test. It may, however, be a marker for a phenotype associated with qacA carriage that confers the clinically relevant effect in CC22, but not CC30. These findings support a hypothesis that qacA carriage is associated with a selective advantage in only some MRSA clones, which could explain results from previous studies. 8, 9, 17 This could be due to reduced uptake of qacA-carrying plasmids by some clones, qacA sequence variation, 36 differences in expression 31 or the requirement for other as yet unidentified cofactors. In the absence of a clear molecular mechanism, we suggest both the clone and qacA carriage status of prevalent isolates may help in deciding on the use of chlorhexidine-based decolonization for infection control purposes, whereas measuring the MIC has little additional value.
We also identified an association between qacA carriage and increasing resistance to non-b-lactam antimicrobial agents. Whilst this association has been shown before, 35 we demonstrate that this effect occurs within defined clones. The qacA gene can be carried on mobile genetic elements that also carry antimicrobial resistance genes, 11, 12, 37, 38 which may explain this link. The limitations of this study include the lack of a validated method for detecting clinically significant reduced chlorhexidine susceptibility to link with qacA genotype or a clinical response, for which there is clearly an urgent need. 7, 14, 31 We also did not have detailed clinical data and matched isolates from a cohort of MRSA-colonized patients to assess whether bloodstream or other infections following chlorhexidine decolonization were more likely in patients colonized with CC22 rather than CC30. This would add additional important clinical evidence for a differential effect of chlorhexidine on these two clones. Finally, unlike the ICU, 8 there was no specific date for a step-change increase in chlorhexidine use or detailed data on compliance with the policy for MRSA decolonization on the general wards; instead, there was a progressive focus on education and guideline adherence from 2004 that coincided with the changing relative prevalence of the two clones. This study did, however, have important strengths. It analysed consecutive BSI isolates over an extended time period and linked clone, qacA carriage and an in vitro susceptibility phenotype with changing MRSA clonal epidemiology in the face of an effective infection control programme.
In summary, this study provides the first evidence that qacA might confer a selective advantage in response to chlorhexidinebased decolonization in some, but not other, MRSA clones. These data, combined with previously published evidence, 8, 17 support a hypothesis that infection control practice may drive changing MRSA epidemiology, perhaps helping to explain the increasing global dominance of CC22 and ST239 clones. This is a particular concern given that these clones have been linked with increased virulence. 20, 28, 39 It raises concerns about the sustainability of decolonization practice and the urgent Otter et al.
need for a better understanding of antiseptic resistance mechanisms and more sensitive and specific phenotypic detection methodologies.
Supplementary data
Tables S1 and S2 are available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/). All ST239-TW isolates selected for phenotypic analysis carried qacA and none carried smr, so ST239-TW was excluded from the interaction terms for these variables. Selection for qacA carriage in MRSA
